Cancer Therapeutics: Market Insight & Pipeline Analysis

Cancer Therapeutics: Market Insight & Pipeline Analysis

Objectives and Scope

The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail the markets for colorectal cancer, prostate cancer, lung cancer, breast cancer, leukemia and non-Hodgkin’s lymphoma. Therapies for other types of cancer are discussed throughout the report, but are limited to the Company Briefs chapter and various tables throughout the report. This report examines these major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market.

Reason for this study

The overall economic cost of cancer is staggering. The US National Institutes of Health (NIH) estimates overall costs of cancer in the U.S. in 2006 at $206.3 billion with $78.2 billion in direct medical costs. Further the WHO predicts that global cases of cancer will rise to 15 million new cases by 2020, an increase of 50% over 2005’s rate. These staggering numbers indicate the importance of effective therapies in treating this epidemic. There is today still a strong need for therapies that more specifically target cancer cells extend progression-free survival rates provide patients with metastatic cancer better treatment options

What questions does this report answer

What is the current market status of cancer therapeutics in general and with regard to specific types of cancer?
What are the strengths, weaknesses, opportunities and threats facing various cancer therapeutics already on the market and ones still in the clinic?
What are the major issues involved in the research and development of more effective cancer therapeutics?
Which new cancer therapeutics in development are nearing the market? And how are they performing in the clinic?

Key features of this Report

Market analysis of cancer therapeutics, by product, class, cancer type, region/country and company
SWOT (strengths, weaknesses, opportunities, threats) analysis for key products on the market as well as for key emerging products
A thorough overview of treatment regimens for various cancers, including detailed information and analysis of first-line, second-line and third-line treatment options
Financial forecasts, by individual cancer therapy and cancer type
Explanations of key technologies and mechanism of action of new classes of cancer drugs
Thorough descriptions of important areas of research and development in cancer therapeutics and cancer vaccines
Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research
Company briefs of stakeholders and companies active in cancer therapy R&D
Over 145 tables/graphs analyzing the current and future market, disease incidence and R&D pipelines for cancer therapeutics
Presentation and analysis of clinical data underscoring success of key therapies
Market share data for leading companies and products in the field
Profiles of leading products in the major cancer markets and analysis of their market impact

What makes this report topical?

Increasing need for healthcare and pharmaceutical cost-containment in both public and private spheres
Focus on introduction of standards in healthcare
Rising involvement of patients in their own healthcare and rising demand for higher quality care
Increasing use of information technology (IT) in healthcare, which provides easier access to various data and analysis
Large investments in new medical technologies and pharmaceuticals requiring high prices, rendering publicly-funded pharmaceutical reimbursement highly desirable

Unique features of this report

Thorough descriptions of key evidence-based medicine practices in major global medical and pharmaceutical markets
Discussion of evidence-based medicine’s future from the point of view of medical advances, not just practical considerations
Analysis of evidence-based medicine from the point of view of pharmaceutical reimbursement
Critical assessment of evidence-based medicine’s advantages and disadvantages 
 

1 Executive Summary

2 The Global Impact of Cancer
2.1 Lung Cancer is the World’s Biggest Cancer Killer
2.2 The Causes of Cancer
2.3 Incidence in Developing Countries
2.4 Cancer Prevention
2.5 Incidence in the United States
2.5.1 Cancer Accounts for over 20% of All Deaths in the US
2.5.2 US Cancer Diagnosis Rates
2.5.3 US Cancer Deaths: Lung Cancer is the Biggest Killer
2.5.4 US Smoking Prevalence
2.5.5 Cancer Survival Rate Has Increased Since 1975
2.5.6 Lifetime Probabilities of Developing Cancer, US
2.6 Economic Impact
2.7 Epidemiology of Select Cancers
2.7.1 Colorectal Cancer
2.7.2 Lung Cancer
2.7.3 Prostate Cancer
2.7.4 Breast Cancer
2.7.5 Pancreatic Cancer
2.7.6 Melanoma
2.7.7 Leukemia
2.7.8 Non-Hodgkin’s Lymphoma
2.8 Unmet Need in Cancer Therapy

3 Product, Company and Geographic Market Analysis
3.1 Cancer Market Overview
3.2 Market Analysis - by Product Class
3.3 Market Analysis - Hormonal Therapies
3.4 Market Analysis - Aromatase Inhibitors
3.5 Market Analysis - Cytotoxics
3.6 Market Analysis - Monoclonal Antibodies
3.7 Market Analysis - Key Products
3.8 Market Analysis - Companies
3.9 Market Analysis - Country and Region
3.9.1 Emerging Cancer Markets
3.10 Market Analysis - Generic Cancer Therapies
3.11 Key Patent Expirations
3.12 Cancer Vaccines - High Market Potential?

4 The Colorectal Cancer Therapy Market
4.1 Current Treatment of Colorectal Cancer
4.1.1 Surgery
4.1.2 Radiation Therapy
4.1.3 The Clinical Use of Cytotoxic Chemotherapy in CRC
4.1.4 Adjuvant Chemotherapy for Advanced CRC
4.1.5 First and Second Line Treatments for CRC
4.1.6 Biologic Therapies for CRC
4.2 Pricing Considerations
4.3 Key Cytotoxics on the Market
4.3.1 Eloxatin
4.3.2 Camptosar
4.3.3 Xeloda
4.4 Key Biologics on the Market
4.4.1 Avastin
4.4.2 Erbitux
4.4.3 Vectibix: A New Monolconal Antibody for the Treatment of Colorectal Cancer
4.4.4 Market Impact of Vectibix
4.5 An Overview of the Market for Colorectal Cancer Therapies
4.6 The Impact of Biologics on the CRC Therapy Market
4.7 SWOT Analysis for Key Products
4.8 Unmet Need in Colorectal Cancer Therapy
4.9 Colorectal Cancer R&D Pipeline Analysis
4.9.1 Key Products in Development
4.1 The Outlook for Colorectal Cancer Therapy
4.11 Financial Forecast

5 The Prostate Cancer Therapy Market
5.1 Current Treatment of Prostate Cancer
5.1.1 Surgery
5.1.2 Radiation Therapy
5.1.3 Hormone Therapy
5.1.4 Cytotoxics
5.1.5 Combination Therapies in the Treatment of Prostate Cancer
5.1.6 Continuous vs. Intermittent Hormonal Treatment
5.2 An Overview of the Market for Prostate Cancer Therapies
5.2.1 Patent Expirations Will Threaten Revenues
5.3 The Prostate Cancer Market Sees Innovation in Drug Delivery Rather than New Drug Type
5.4 SWOT Analysis for Key Products
5.5 Unmet Need in Prostate Cancer Therapy
5.6 Prostate Cancer R & D Pipeline Analysis
5.6.1 Key Products in Late-Stage Development
5.7 SWOT Analysis for Key Products in Development
5.8 The Outlook for Prostate Cancer Therapy
5.9 Financial Forecast

6 The Lung Cancer Therapy Market
6.1 Current Treatment of Lung Cancer
6.1.1 Surgery
6.1.2 Radiation Therapy
6.1.3 Chemotherapy
6.1.4 Targeted Therapies
6.2 Market Analysis
6.2.1 A Strong Future for Alimta?
6.3 A Progress Report on New Targeted Therapies
6.3.1 Iressa Proves a Disappointment
6.3.2 Tarceva
6.3.3 Avastin
6.4 SWOT Analysis for Key Products
6.5 Unmet Need in Lung Cancer Therapy
6.6 Lung Cancer R&D Pipeline Analysis
6.6.1 Mixed Clinical Results for Avastin
6.6.2 Erbitux Improves Lung Cancer Survival
6.6.3 Zactima
6.6.4 Recentin Trial
6.7 The Outlook for Lung Cancer Therapies
6.8 Financial Forecast

7 The Breast Cancer Therapy Market
7.1 Current Treatment of Breast Cancer
7.1.1 Surgery
7.1.2 Radiation Therapy
7.1.3 Hormonal Therapy
7.1.4 Cytotoxics
7.1.5 Herceptin
7.2 Market Analysis
7.2.1 Market Analysis - Cytotoxics
7.2.2 Market Analysis - Key Products
7.3 SWOT Analysis for Key Products
7.4 Unmet Need in Breast Cancer Therapy
7.5 Breast Cancer R&D Pipeline Analysis
7.5.1 Taxol vs. Taxotere in Early Breast Cancer
7.5.2 Taxane Combinations vs. Anthracyclines
7.5.3 Zometa and Early Breast Cancer Treatment
7.5.4 Tykerb plus Herceptin
7.6 The Outlook for Breast Cancer Therapy
7.7 Financial Forecast

8 The Leukemia Therapy Market
8.1 Comparison of Leukemia Types and Incidence Rates
8.2 Treatment Options for Leukemia by Type
8.2.1 Acute Lymphocytic Leukemia (ALL)
8.2.2 Chronic Lymphocytic Leukemia (CLL)
8.2.3 Acute Myelogenous Leukemia (AML)
8.2.4 Chronic Myelogenous Leukemia (CML)
8.3 Survival Rates
8.4 Death Rates
8.5 Key Therapies - Gleevec
8.6 Key Therapies - Sprycel
8.7 Key Therapies - Tasigna
8.8 Key Therapies - Ceflatonin
8.9 Market Analysis
8.1 SWOT Analysis of the Main Drugs Used in CML
8.11 New Therapies in Development
8.11.1 Phase III Trial for Sprycel Allows Dose Change
8.11.2 Sprycel for Gleevec-Resistant CML
8.11.3 A Phase III Trial of High-dose Gleevec
8.11.4 1.10.3 A Phase III Trial Comparing Tasigna with Gleevec
8.11.5 Tasigna for Gleevec-Resistant CML
8.11.6 Ofatumumab for CLL
8.12 The Outlook for CML Therapies

9 The Non-Hodgkin’s Lymphoma Therapy Market
9.1 The Types of Non-Hodgkin’s Lymphoma
9.2 The Stages of NHL
9.3 Treatment for NHL: Chemotherapy and Radiotherapy
9.3.1 Chemotherapy
9.3.2 Hematopoietic Stem Cell Transplantation
9.3.3 Antibody Therapies for NHL
9.3.4 Bexxar
9.3.5 Zevalin
9.3.6 Rituxan
9.4 The Market for NHL Therapies
9.5 NHL R&D Pipeline Analysis
9.5.1 Enzastaurin
9.5.2 Galiximab
9.5.3 Pixantrone
9.5.4 Mozobil
9.6 The Outlook for NHL Therapies

10 Company Briefs
10.1 Aeterna Zentaris
10.2 Amgen
10.3 Antigenics
10.4 Antisoma
10.5 AstraZeneca
10.6 Bayer Schering
10.7 Biogen Idec
10.8 Bristol-Myers Squibb
10.9 Celgene
10.1 Cell Genesys
10.11 Dendreon
10.12 Eli Lilly
10.13 Genentech
10.14 Genitope
10.15 Genmab
10.16 Genta
10.17 Genzyme (Oncology)
10.18 GlaxoSmithKline
10.19 ImClone Systems Incorporated
10.2 Lorus Therapeutics
10.21 Medarex
10.22 MedImmune
10.23 Merck & Co.
10.24 Novartis
10.25 Oncothyreon (formerly Biomira)
10.26 Pfizer
10.27 Roche
10.28 Sanofi Aventis
10.29 Seattle Genetics
10.3 Vaccinogen
10.31 Vical

TABLES
Table 2.1 Cancer Incidence and Deaths, by Type of Cancer 2007
Table 2.2 Cancer Deaths Worldwide by Rank, 2002
Table 2.3 Factors Involved in Cancer Development
Table 2.4a Cancer Incidence and Mortality Worldwide 2002
Table 2.4b World Cancer Incidence, Prevalence and Mortality by Country by Percentage, 2005
Table 2.5 Factors Involved in Cancer Prevention
Table 2.6 The Leading Causes of Death in the US 2005
Table 2.7 Change in US Death Rates by Cause 1950 and 2005
Table 2.8 Estimated New Cancer Cases, 2008
Table 2.9 Estimated US Cancer Deaths, 2008
Table 2.10 Trends in US Five Year Survival Rates (%), 1975-2003
Table 2.11 Lifetime Probability of Developing Cancer, 2000-2004
Table 2.12 Breast Cancer Survival Rates, by Stage
Table 2.13 Breast Cancer Overall Survival Rate
Table 3.1 Principal Cancer Drugs, by 2007 Global Revenues ($mn) and Main Indication
Table 3.2 Global Market Share (%) by Cancer Type 2007
Table 3.3 Global Revenues ($mn) by Cancer Type 2002-2007
Table 3.4 Global Market Share (%) by Drug Type 2007
Table 3.5 Global Market Share (%) by Drug Type 2006
Table 3.6 Global Revenues ($mn) by Drug and Drug Type 2007
Table 3.7 Global Revenues ($mn) by Drug Type 2002-2007
Table 3.8 Global Revenues ($mn) of Hormonal Therapies 2002-2007
Table 3.9 Global Revenues ($m) of Aromatase Inhibitors and Nolvadex 2002-2007
Table 3.10 Global Revenues ($mn) of Cytotoxics 2002-2007
Table 3.11 Global Revenues ($mn) of Monoclonal Antibodies 2002-2007
Table 3.12 Global Revenues ($m) and Market Share (%) by Drug in Order of Revenues 2007
Table 3.13 Global Revenues ($m) by Drug 2002-2007
Table 3.14 Global Revenues ($mn) by Company 2007
Table 3.15 Market Share (%) and Revenue by Company 2007
Table 3.16 Global Revenues ($m) by Company 2002-2007
Table 3.17 Company CAGR 2002-2007
Table 3.18 Global Cancer Market (%) by Country, 2007
Table 3.19 Key Patent Expirations in the US Cancer Market
Table 4.1 The Stages of Colorectal Cancer
Table 4.2 Principal Therapies for Colorectal Cancer 2008
Table 4.3 Patent Approval and Expiry dates of Drugs in the Colorectal Market
Table 4.4 Average Cost of an 8 Week Course of Key Colorectal Cancer Drugs
Table 4.5 Global Sales ($m) of Eloxatin 2002-2007
Table 4.6 Global Sales ($m) of Camptosar 2002-2007
Table 4.7 Global Sales ($m) of Xeloda 2002-2007
Table 4.8 Global Sales ($m) of Avastin 2002-2007
Table 4.9 Global Sales ($m) of Erbitux, 2002-2007
Table 4.10 Global Sales ($m) of Vectibix 2002-2007
Table 4.11 Global Sales of Colorectal Cancer Drugs ($m) 2002-2007
Table 4.12 Sales ($m) of Biologic Therapies for Colorectal Cancer
Table 4.13 Global Revenues ($m) of Cytotoxics for Colorectal Cancer
Table 4.14 Global Market Share (%) of Biologics and Cytotoxics
Table 4.15 Global Market Share of Colorectal Cancer Therapies (%),
Table 4.16 Role of Chemotherapy in Colorectal Survival Rates
Table 4.17 Top 4 Most Active Companies Involved in Colorectal Cancer
Table 4.18 Key Colorectal Cancer Therapies in R&D Pipeline
Table 4.19 Colorectal Cancer Therapies Market Financial Forecast
Table 5.1 The Stages of Prostate Cancer
Table 5.2 Key Prostate Cancer Therapies
Table 5.3 Global Revenues ($m) for the Prostate Cancer Market
Table 5.4 Global Hormonal Therapies Revenues ($m) in 2006 and
Table 5.5 Global Hormonal Drugs Market Share (%), in 2006 and
Table 5.6 Key US Patent Expirations in Prostate Cancer Market
Table 5.7 Hormonal Drugs by Length of Depot
Table 5.8 Number of Therapies in Development by the Top 5
Table 5.9 Key Prostate Cancer Therapies in R&D Pipeline
Table 5.10 Prostate Cancer Therapies Market Financial Forecast
Table 6.1 Table Stages of Lung Cancer
Table 6.2 Diagnosis and Survival Rates for NSCLC in US
Table 6.3 Key Therapies Utilized in the Treatment of Lung Cancer
Table 6.4 Principal Second-Line Therapies for NSCLC
Table 6.5 Clinical Efficacy Comparisons for 2nd Line Therapies for NSCLC
Table 6.6 Global Lung Cancer Therapy Revenues ($m), 2002-2007
Table 6.7 Key Lung Cancer Therapies in R&D Pipeline
Table 6.8 Lung Cancer Therapies Market Financial Forecast 2008-2012 ($m)
Table 6.9 Key Patent Expirations in Lung Cancer Market
Table 7.1 Principal Drugs Used in Breast Cancer
Table 7.2 Stages of Breast Cancer
Table 7.3 Profiles of Key Aromatase Inhibitors on Market
Table 7.4 Profiles of Single-Agent Chemotherapies for Metastatic Breast Cancer
Table 7.5 Principal Non-chemotherapeutic Therapies for Breast Cancer
Table 7.6 Breast Cancer Therapies US Patent Information
Table 7.7 Revenues ($m) for the Principal Therapies for Breast Cancer 2002-2007
Table 7.8 World Market Share (%) of Herceptin and Aromatase Inhibitors in the Breast Cancer Market 2006 and 2007
Table 7.9 Global Market Share (%) of Key Therapies in the Breast Cancer Market 2007
Table 7.10 Major Uses for Popular Anti-Cancer Agents
Table 7.11 Key Breast Cancer Therapies in R&D Pipeline
Table 7.12 Femara vs Arimidex in Clinical Trial Results
Table 7.13 Breast Cancer Therapies Market Financial Forecast 2008-2012 ($m)
Table 8.1 Different Leukemias by Percentage, Estimated 2007
Table 8.2 Four Major Types of Leukemia
Table 8.3 Key Drugs on the Global CML Market, 2008
Table 8.4 Global CML Market Revenues ($m), 2003-2008
Table 8.5 Key Leukemia Therapies in R&D Pipeline
Table 8.6 CML Therapies Market Financial Forecast 2008-2012 ($m)
Table 9.1 Drugs Used to Treat NHL, by Patent Expiry
Table 9.2 Global Sales of Rituxan 2002-2007
Table 9.3 Key NHL Therapies in R&D Pipeline
Table 9.4 NHL Therapies Market Financial Forecast 2008-2012
Table 10.1 Amgen’s Oncology R&D Pipeline
Table 10.2 Clinical Development Status of Oncophage
Table 10.3 AstraZeneca’s Oncology Portfolio
Table 10.4 AstraZeneca’s Oncology Pipeline
Table 10.5 Bayer Schering’s Oncology Pipeline
Table 10.6 Biogen Idec’s Oncology Pipeline
Table 10.7 Bristol-Myers Squibb’s Oncology Portfolio
Table 10.8 Celgene’s Oncology Pipeline
Table 10.9 Clinical Development of GVAX
Table 10.10 Dendreon’s Vaccine Pipeline
Table 10.11 Eli Lilly’s Oncology Pipeline
Table 10.12 Genentech’s Oncology Pipeline
Table 10.13 Genmab’s Oncology Pipeline
Table 10.14 Genzyme’s Oncology Pipeline
Table 10.15 GlaxoSmithKline’s Oncology Portfolio
Table 10.16 GlaxoSmithKline’s Oncology Pipeline
Table 10.17 ImClone’s Oncology Pipeline
Table 10.18 Medarex’s Oncology Pipeline
Table 10.19 Oncothyreon’s Oncology Pipeline
Table 10.20 Pfizer’s Late-Stage Oncology Pipeline
Table 10.21 Sanofi-Aventis’ Oncology Pipeline
Table 10.22 Seattle Genetics’ Oncology Pipeline

GRAPHS
Graph 3.1 Global Market Share (%) by Cancer Type 2007
Graph 3.2 Global Revenues ($m) by Cancer Type 2002-2007
Graph 3.3 Global Market Share (%) by Drug Type 2007
Graph 3.4 Global Market Share (%) by Drug Type 2006
Graph 3.5 Global Revenues ($mn) by Drug Type 2002-2007
Graph 3.6 Global Revenues ($m) of Hormonal Therapies 2002-2007
Graph 3.7 Global Revenues ($mn) of Aromatase Inhibitors and
Graph 3.8 Global Revenues ($mn) of Cytotoxics 2002-2007
Graph 3.9 Global Revenues ($mn) of Monoclonal Antibodies 2002-07
Graph 3.10 Leading Cancer Drugs by Market Share (%) 2007
Graph 3.11 Company Revenues by Market Share (%) 2007
Graph 3.12 Global Revenues ($m) by Company 2002-2007
Graph 3.13 Global Cancer Market (%) by Country/Region 2007
Graph 4.1 Global Sales of Colorectal Cancer Therapies ($m) 2002-2007
Graph 4.2 Market Share of Key Colorectal Cancer Therapies (%)
Graph 4.3 Number of Colorectal Cancer Therapies in R&D by Clinical
Graph 4.4 Colorectal Cancer Therapies Market Financial Forecast
Graph 5.1 Global Revenues ($m) for the Prostate Cancer Market
Graph 5.2 Global Hormonal Therapy Market Share (%), 2007
Graph 5.3 Prostate Cancer Therapies in R&D, by Clinical Trial Phase
Graph 5.4 Prostate Cancer Therapies Market Financial Forecast
Graph 6.1 Global Lung Cancer Therapy Revenues ($m), 2002-2007
Graph 6.2 Lung Cancer Therapies in R&D, by Clinical Trial Phase
Graph 6.3 Lung Cancer Therapies Market Financial Forecast 2008-2012 ($m)
Graph 7.1 Revenues ($m) for Principal Therapies for Breast Cancer 2002-2007
Graph 7.2 Global Market Share (%) of Key Therapies in the Breast Cancer Market 2007
Graph 7.3 Breast Cancer Therapies Market Financial Forecast 2008-2012 ($m)
Graph 8.1 Global CML Market Revenues ($m), 2003-2007
Graph 8.2 CML Therapies Market Financial Forecast 2008-2012 ($m)
Graph 9.1 Global Sales of Rituxan 2002-2007
Graph 9.2 Number of Drugs in NHL Trials
Graph 9.3 NHL Therapies Market Financial Forecast 2008-2012 Graph 2.1 Total Pharma R&D Expenditure (US$ billion)
Graph 2.2 Total Pharma Clinical Outsourcing Expenditure (US$ billion)
Graph 2.3 Global Clinical Research Personnel
Graph 2.4 Pivotal Trial Milestones
Graph 2.5 Case Report Form Queries/Page Screen
Graph 2.6 Contract Research Organization Global Industry Revenues
Graph 2.7 Location of New Offices for US-Based CROs
Graph 3.1 Fee Partition
Graph 3.2 Clinical Trials Registered in Western Pharmaceutical Companies in Poland 1995-2001
Graph 3.3 Clinical Trials Registered by Western Pharmaceutical Companies in Hungary 1992-2000
Graph 3.4 Drug Sales in the Eight New EU Member States in 2004
Graph 4.1 Number of Human Clinical Trials in Selected Countries (2006)
Graph 5.1 Cost Savings of Clinical Trials in India
Graph 6.1 International Clinical Trials Cost Comparisons in Terms of Overall Pharmaceutical Manufacturing Costs
Graph 6.2 Mean Fee per Patient (in AU$)
Graph 6.3 Schemes, Location and Phases of Clinical Trials in Australia
Graph 7.1 Proposed EDCTP Expenditure (203-2007)
Graph 8.1 Estimated Annual National Health Expenditure as a Proportion of GDP in Select Latin American Countries
Graph 8.2 Leading Causes of Death in Latin America
Graph 8.3 Key Areas of Latin American Investigators’ Expertise
Graph 8.4 Most Common Pending Issues from the Brazilian Ministry of Health
Graph 8.5 Therapeutic Breakdown of Current Clinical Research in Argentina
Graph 8.6 Lilly Argentina’s Clinical Trial Activity (1997-2000)
Graph 8.7 Pfizer Argentina’s Clinical Research Activity
Graph 8.8 Sponsors of Clinical Research in Argentina
Graph 8.9 Total Approved Clinical Studies in Brazil, by Year
Graph 8.10 Latin American Pharmaceutical Market in 2005 by Key Countries
Graph 9.1 Compensation Cost Indices
Graph 9.2 Population Related Indices
Graph 9.3 Cardiovascular Disease Index
Graph 9.4 Pulmonary Index
Graph 9.5 Cancer Index
Graph 9.6 Infectious Disease Index
Graph 9.7 Disease Incidence Index
Graph 9.8 Clinical Research Rank Order
Graph 9.9 Research Personnel Indicators, Rank Order
Graph 9.10 Study Site Indices
Graph 9.11 Business Environment Indices
Graph 9.12 Clinical Trial Global Attractiveness Index